Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026)
Protalix BioTherapeutics (PLX) recorded quarterly Non Operating Income of -$5000.0 in Q1 2026, up 95.76% quarter-over-quarter from -$118000.0 in Q4 2025, and down 101.21% on a YoY basis from $413000.0 in Q1 2025.
Protalix BioTherapeutics (PLX) Non Operating Income (2012 - 2026) Analysis & Trends
Protalix BioTherapeutics' Non Operating Income history runs 15 years deep, the most recent figure standing at -$5000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 101.21% year-over-year to -$5000.0; the TTM figure through Mar 2026 stood at -$526000.0 (down 199.81% YoY), while the FY2025 annual figure was -$108000.0, down 145.57% from the prior year.
- Non Operating Income was -$5000.0 for Q1 2026 at Protalix BioTherapeutics, up from -$118000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $413000.0 in Q1 2025 to a low of -$811000.0 in Q4 2023.
- Historically, Non Operating Income has averaged -$185470.6 across 5 years, with a median of -$118000.0 in 2025.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 507.37% in 2023, then soared 235.77% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$715000.0 in 2022, then declined by 13.43% to -$811000.0 in 2023, then soared by 113.19% to $107000.0 in 2024, then sank by 210.28% to -$118000.0 in 2025, then soared by 95.76% to -$5000.0 in 2026.
- The last three Non Operating Income figures came in at -$5000.0 (Q1 2026), -$118000.0 (Q4 2025), and $108000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | -511,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | -148,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | -811,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | -774,000.00 |
| Mar 31, 2023 | -477,000.00 |
| Dec 31, 2022 | -715,000.00 |
| Sep 30, 2022 | -442,000.00 |
| Jun 30, 2022 | 190,000.00 |
| Mar 31, 2022 | -416,000.00 |
| Dec 31, 2021 | -910,000.00 |
| Sep 30, 2021 | -2.31 Mn |
| Jun 30, 2021 | -2.08 Mn |